CVR 44427923Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)GentofteFounded 9 Nov 2023
CVR holds no employment figures for this company.
Compiled by Dandex from the Central Business Register (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish company data. Connect it once and ask about Spectoceutics ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set Up DandexGross profit
-17.3K
DKK, annual report 2025
Result
-13.5K
DKK, annual report 2025
Equity
19.4K
DKK, annual report 2025
Dunnock Holding ApSCVR 42661287, 90% to under 100% of capital and votes, since 9 Nov 2023
Anders Ohlhues Baandrup5% to under 10% of capital and votes, since 9 Nov 2023
Carsten Højersince 9 Nov 2023
5% to under 10% of capital and votessince 9 Nov 2023
CVR 4266128790% to under 100% of capital and votessince 9 Nov 2023
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
Decided by Dandex with fixed rules from the CVR register and the filed annual reports, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
| Metric | 2024 | 2025 |
|---|---|---|
| Gross profit | -7 | -17 |
| Operating profit | -7 | -17 |
| Result for the year | -7 | -14 |
| Equity | 33 | 19 |
| Total assets | 34 | 20 |
| Credit metrics (Dandex calculations) | ||
| EBITDA | -7 | -17 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) | Pro: in the Pro plan, see pricingEBITDA as a share of gross profit. | |
| Net interest-bearing debt (NIBD, nettorentebærende gæld) | Pro: in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | |
| Gearing, NIBD / EBITDA | Pro: in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | |
| Interest coverage (rentedækning) | Pro: in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | |
| Adjusted equity ratio (justeret soliditetsgrad) | Pro: in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | |
| ROIC (afkast af investeret kapital) | Pro: in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | |
| Capex % of sales (investeringer i procent af omsætningen) | Pro: in the Pro plan, see pricingCapex as a share of revenue. | |
| FCFF / EBITDA (pengestrømskonvertering) | Pro: in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | |
DKK thousands. Annual reports via XBRL. Not every period is a full year: 2024 covers 14 months (9 Nov 2023 to 31 Dec 2024). Changes against it compare periods of different length.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Dandex has recorded no changes to this company since it began following the register.
Pro: in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (Nyt lederskab), New company (Ny virksomhed), Ownership change (Ejerskifte), Relocation (Flytning), Growth surge (Vækstspurt), Headcount decline (Nedgang i ansatte), Restructuring (Omstrukturering), Industry change (Brancheskift), Board change (Bestyrelsesændring), Dissolution (Ophør), Distress warning (Risikoadvarsel), Fund investment (Fondsinvestering), Fund exit (Fondsexit), Fund board seat (Fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For Spectoceutics ApS, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 11 Nov 2026. Text such as the signing rule and purpose is shown as registered.
1 registration, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Stiftelsesdato: 09.11.2023.
Virkningsdato: 09.11.2023.
Seneste vedtægtsdato: 09.11.2023.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
Anders Ohlhues Baandrup, den 09.11.2023, CVR-NR. 42661287 Dunnock Holding ApS, Solbakkevej 37A, 2820 Gentofte, den 09.11.2023.
Direktion:
Carsten Højer, den 09.11.2023.
Selskabet tegnes af en direktør.
Første regnskabsår:
09.11.2023 - 31.12.2024.
Regnskabsår:
01.01 - 31.12.
Formål:
Selskabets formål er at udvikle, markedsføre, licensere og sælge ny teknologi samt dermed beslægtede aktiviteter
1 registered in CVR.
P-number 1029829256Solbakkevej 37, 2820 Gentofte
